Yousif Capital Management LLC Sells 22,586 Shares of Ralliant Corporation $RAL

by · The Cerbat Gem

Yousif Capital Management LLC lessened its position in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 38.8% in the third quarter, HoldingsChannel.com reports. The firm owned 35,685 shares of the company’s stock after selling 22,586 shares during the quarter. Yousif Capital Management LLC’s holdings in Ralliant were worth $1,561,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Farmers & Merchants Investments Inc. bought a new stake in shares of Ralliant in the 2nd quarter valued at $662,000. GAMMA Investing LLC bought a new position in Ralliant during the second quarter worth $56,000. Alpha Omega Wealth Management LLC acquired a new position in Ralliant in the second quarter valued at $213,000. Public Employees Retirement System of Ohio bought a new stake in Ralliant during the second quarter valued at $1,799,000. Finally, TD Private Client Wealth LLC bought a new stake in Ralliant during the second quarter valued at $284,000.

Ralliant Stock Performance

Shares of NYSE:RAL opened at $51.27 on Tuesday. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. Ralliant Corporation has a 52-week low of $40.70 and a 52-week high of $55.08. The business has a 50 day moving average price of $47.84. The company has a market capitalization of $5.78 billion and a price-to-earnings ratio of 40.37.

Ralliant (NYSE:RAL – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The firm had revenue of $529.10 million for the quarter, compared to analyst estimates of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RAL. Royal Bank Of Canada lifted their price objective on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Ralliant in a report on Monday, December 15th. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Oppenheimer lifted their price objective on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, Morgan Stanley started coverage on shares of Ralliant in a research note on Tuesday, September 2nd. They set an “overweight” rating and a $55.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $57.89.

Get Our Latest Report on Ralliant

Ralliant Profile

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Recommended Stories

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).